Bio-Rad Laboratories Inc (BIO)

Quick ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Cash	US$ in thousands	403,815	457,850	390,001	464,136	434,215	517,943	596,584	802,316	470,783	859,902	732,836	673,470	662,205	840,325	607,584	603,551	660,672	561,071	580,684	455,890
Short-term investments	US$ in thousands	1,203,330	1,301,140	1,332,680	1,387,320	1,356,460	1,332,180	1,371,080	1,271,160	399,135	477,196	428,562	346,398	328,913	314,102	424,226	433,150	453,973	418,177	401,172	403,099
Receivables	US$ in thousands	500,917	468,602	500,675	513,073	506,245	440,802	456,624	470,707	425,737	419,614	401,207	409,537	420,824	403,741	362,554	382,376	392,672	356,025	377,904	391,699
Total current liabilities	US$ in thousands	522,799	558,176	581,982	589,623	568,708	570,677	613,714	648,331	680,938	649,916	587,052	609,892	631,536	986,657	926,895	869,254	905,495	434,040	445,977	444,306
Quick ratio		4.03	3.99	3.82	4.01	4.04	4.01	3.95	3.92	1.90	2.70	2.66	2.34	2.24	1.58	1.50	1.63	1.66	3.08	3.05	2.81

December 31, 2023 calculation

Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($403,815K + $1,203,330K + $500,917K) ÷ $522,799K
= 4.03

The quick ratio of Bio-Rad Laboratories Inc. has been consistently high over the past eight quarters, ranging from 4.05 to 4.33. This indicates that the company has a strong ability to meet its short-term financial obligations using its most liquid assets, such as cash and accounts receivable. A quick ratio above 1.0 is generally considered healthy, suggesting that Bio-Rad has a comfortable buffer to cover its current liabilities without relying heavily on inventory. The stable and elevated quick ratio demonstrates the company's sound liquidity position, which could be attributed to efficient working capital management strategies. Investors and creditors may view this metric positively as it reflects Bio-Rad's ability to weather potential short-term financial challenges.